The efficacy and safety of ɛ-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis
Article first published online: 13 DEC 2005
Alimentary Pharmacology & Therapeutics
Volume 23, Issue 1, pages 115–120, January 2006
How to Cite
GUNAWAN, B. and RUNYON, B. (2006), The efficacy and safety of ɛ-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Alimentary Pharmacology & Therapeutics, 23: 115–120. doi: 10.1111/j.1365-2036.2006.02730.x
- Issue published online: 13 DEC 2005
- Article first published online: 13 DEC 2005
- Publication data Submitted 8 September 2005 First decision 11 September 2005 Resubmitted 29 September 2005 Accepted 14 October 2005
Patients with decompensated cirrhosis are at risk for hyperfibrinolysis; this is potentially fatal. ɛ-aminocaproic acid has been used to treat patients with hyperfibrinolysis; however, the data about its benefit in the setting of cirrhosis are minimal.
To analyse the efficacy of ɛ-aminocaproic acid and its safety in cirrhotic patients with hyperfibrinolysis.
All patients with an abnormal euglobin lysis time who were admitted to Rancho Los Amigos Medical Center from 1 January 2001 to 31 December 2002 were included in the study. Their medical records were reviewed and analysed.
There were 60 cirrhotic patients with shortened euglobin lysis time. Fifty-two patients received ɛ-aminocaproic acid. Of the 52 patients, seven had one or more bleeding episodes with the subcutaneous or soft tissue bleeding as the most common indication for ɛ-aminocaproic acid use. Of the 37 patients, 34 (92%) had improvement or resolution of their bleeding. Only two (3%) patients had ɛ-aminocaproic acid treatment discontinued because of minor side effects, rash and lightheadedness. There were no thromboembolic complications of treatment.
ɛ-aminocaproic acid was found to be effective and safe for treatment of hyperfibrinolysis in patients with cirrhosis.